UNITY BIOTECHNOLOGY INC (UBX) Stock Overview
USA - NASDAQ:UBX - US91381U2006 - Common Stock
UBX Key Statistics, Chart & Performance
The current stock price of UBX is 0.2001 USD. In the past month the price decreased by -70.62%. In the past year, price decreased by -87.09%.
UBX Latest News, Press Relases and Analysis
UBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About UBX
Company Profile
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. The company has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an α-Klotho hormone drug candidate, is being researched for multiple neurology indications.
Company Info
UNITY BIOTECHNOLOGY INC
285 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 16
Phone: 16504161192
UNITY BIOTECHNOLOGY INC / UBX FAQ
What does UBX do?
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. The company has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an α-Klotho hormone drug candidate, is being researched for multiple neurology indications.
What is the current price of UBX stock?
The current stock price of UBX is 0.2001 USD. The price decreased by -33.41% in the last trading session.
Does UNITY BIOTECHNOLOGY INC pay dividends?
UBX does not pay a dividend.
What is the ChartMill rating of UNITY BIOTECHNOLOGY INC stock?
UBX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of UNITY BIOTECHNOLOGY INC (UBX)?
UNITY BIOTECHNOLOGY INC (UBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
What is the market capitalization of UBX stock?
UNITY BIOTECHNOLOGY INC (UBX) has a market capitalization of 3.44M USD. This makes UBX a Nano Cap stock.
Who owns UNITY BIOTECHNOLOGY INC?
You can find the ownership structure of UNITY BIOTECHNOLOGY INC (UBX) on the Ownership tab.
UBX Technical Analysis
UBX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to UBX. UBX has a bad profitability rating. Also its financial health evaluation is rather negative.
UBX Financial Highlights
Over the last trailing twelve months UBX reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 23.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
UBX Forecast & Estimates
8 analysts have analysed UBX and the average price target is 3.06 USD. This implies a price increase of 1429.24% is expected in the next year compared to the current price of 0.2001.
For the next year, analysts expect an EPS growth of 4.15% and a revenue growth -100% for UBX